Poly(ethylene glycol)-conjugated (or PEGylated) proteins are an increasingly important class of therapeutic proteins that offer improved in vivo circulation half lives over their corresponding native forms. Their production involves covalent attachment of one or more poly(ethylene glycol) molecules to a native protein, followed by purification. Because of the extremely high costs involved in producing native therapeutic proteins it is important that subsequent PEGylation processes are as efficient as possible. In this paper, reaction engineering and purification issues for PEGylated proteins are reviewed. Paramount considerations for PEGylation reactions are specificity with respect to the conjugation site and overall yield. Batch PEGylation reaction methods are discussed, along with innovative methods using packed bed or "on-column" approaches to improve specificity and yield. Purification methods are currently dominated by ion exchange and size exclusion chromatography. Other methods in common use for protein separations, including hydrophobic interaction chromatography, affinity chromatography and membrane separations, are rarely used in PEGylated protein purification schemes. A better understanding of the effects of PEGylation on the physicochemical properties of proteins (isoelectric point, surface charge density and distribution, molecular size and relative hydrophobicity) and interactions between PEGylated proteins and surfaces is needed for the future development of optimal purification processes and media.
Introduction
Poly(ethylene glycol) or PEG is a neutral, hydrophilic polyether which exhibits little reactivity unless modified with functional groups. It has many uses and applications including those related to its use as a non-toxic, non-immunogenic lubricant or carrier in pharmaceutical formulations. The polymer can be prepared with relatively controlled average MW and modified with various functional groups. Abuchowski and Davis et al. (1977) observed that covalent attachment of PEG to proteins results in active conjugates that are non-immunogenic, non-antigenic and have greatly increased in vivo circulation half-lives. These changes appear to be mainly due to significantly increased molecular size (hydrodynamic radii), plus surface alteration and protection (in effect masking) by the neutral, chemically inert, hydrophilic PEG polymers; whose coating effects were also noted by other researchers including Sehon et al., Merrill et al., Hoffman et al., Harris et al., Johansson et al., and Holmberg et al. (see in Harris, 1992a, b; Harris and Zalipsky, 1997; Veronese and Harris, 2002; Zalipsky, 1995) . PEGylation of therapeutic proteins reduces renal clearance rates and protects from proteolytic and other degradation often resulting in enhanced medical efficacy. Other benefits of PEGylation may include improved physical and thermal stability, as well as solubility. The latter is particularly important with regard to biopharmaceutical formulation and delivery. Over the past three decades many proteins and other substances have been PEGylated for use as pharmaceuticals, reaction catalysts, drug delivery agents, and biopharmaceuticals. Successful protein (ADAGEN™® from Enzon), and granulocyte colony stimulating factor (Neulasta® from Amgen). Many other PEGylated proteins are currently under development.
Protein PEGylation has been reviewed extensively by many authors including a recent review by Veronese and Harris in a special issue of Advanced Drug Delivery Reviews dedicated to PEGylation (Veronese and Harris, 2002) . Other notable reviews include books edited by Harris (1992b) , plus Harris and Zalipsky (1997) , as well as papers by Zalipsky (1995) , Zalipsky and Lee (1992) , Roberts et al. (2002) , Kodera et al. (1998) , Greenwald (2001) and Pasut et al. (2004) . However apart from a brief 1998 review (Bailon and Berthold, 1998) , little attention has been paid to production and separation aspects related to PEG-proteins.
This review focuses on some biochemical and biomolecular engineering aspects of protein PEGylation. Specific issues of clinical efficacy, biomedical effects, biological function, analysis and conjugation chemistry are not explored except in so far as they are relevant to engineering aspects, which mainly involve reaction engineering (physical control of reaction specificity and yield), separations and other aspects related to production. Some of the points discussed are relevant for PEGylation and processing of substances other than proteins including lower MW pharmaceuticals, or for substances modified by hydrophilic polymers other than PEG.
Processing challenges that arise in the development of PEGylated proteins, as well as other PEGylated substances, often concern controlling the position of conjugation (positional isomers or PEGamers) and the number of PEG adducts or extent of PEGylation (N). Therapeutic drugs should ideally be homogeneous products with well-defined activities, and acceptable side-effects. Variations in the position and number of PEG adducts gives rise to variations in characteristics relevant to clinical and other application related effects. These include enzymatic or other activities, circulation half-life, immunogenicity and clearance (Harris, 1992b; Harris and Zalipsky, 1997; Pasta et al., 1988; Zalipsky, 1995) . Product homogeneity can be obtained by maximising reaction specificity and/or implementing effective product purification. Given the high cost of producing therapeutic proteins prior to their PEGylation, achieving high purity of PEGylated forms at the expense of yield (the usual trade-off) is not an economically wise option. Improving reaction specificity and developing effective and efficient purification processes are critical areas where the biochemical engineer can make valuable contributions. Several approaches are available. Related engineering can be organised in relation to (a) PEGylation site and chemistry engineering, (b) PEGylation reaction engineering, and (c) purification process engineering. The first is affected by recent trends to (i) undertake controlled PEGylation at defined protein residues (sites) and (ii) use larger molecular PEG molecules in an effort to reduce the number of sites (N) which need to be modified to effect the desired results. In addition all three engineering aspects are affected by the physical properties of PEG polymers, including their neutral, hydrophilic nature and relatively large viscosity radii.
PEGylation Site, Chemistry and Polymer Engineering
The most common chemistry for PEGylation targets the ε-amino group of surface lysine residues. Lysines account for approximately 10% of amino acids in a typical protein so most proteins including antibodies have numerous surface-available lysine residues, which present both opportunities and challenges. Their availability makes conjugation straightforward but the large number of conjugation sites presents difficulty in obtaining a specific number of PEG adducts and gives rise to PEGamer mixtures. Control of PEGylation site(s) reduces random PEGylation. In one simple approach amino group modification can controlled to some extent by reaction pH so that conjugation tends to occur at the α-amino of the N-terminal (Kinstler et al., 2002; Kinstler et al., 1996) . Lysine or other amine groups are not the only protein (residue) groups open to covalent modification.
Specific chemistries can be used to target conjugation to a variety of sites on a protein e.g. (Zalipsky, 1995) . Such an approach eliminates problems related to PEGylation altering a residue so as to negatively affect the activity of the protein or molecules being modified. If the native protein has a free cysteine residue not associated with the active site, then conjugation with a thiol-selective functionalised PEG (such as maleimide-PEG) may be an option. However, such cases, when they occur naturally, are fortuitous and by no means typical. Proteins can be engineered by site-directed mutation or otherwise chemically modified to fabricate a suitable conjugation site (e.g. see Chapman, 2002; Chapman et al., 1999; Roberts et al., 2002; Zalipsky, 1995) , Such approaches have disadvantages in terms of time to market, cost of development and risk compared with developing a PEGylated form of an already-approved protein.
The latter is significant given that the new mutated or chemically altered protein will require more certification to obtain regulatory approval (see Hoyle, 1991) .
Nevertheless approaches related to PEGylation of mutated or modified proteins may be justifiable in terms of ensuring the PEGylated product has adequate activity and function (see Chapman, 2002; Harris, 1992b; Harris and Zalipsky, 1997) .
which was PEGylated at the N-terminus to avoid PEGylation of lysine residues close to the active site in the natural form. Remarkably, despite belief that TNF requires some lysine groups for activity, acceptable activity was obtained. Pettit et al. (1996) used site directed mutagenesis to control PEGylation and the resulting activity of interleukin protein. Yang et al. (2003) used site-directed mutagenesis to insert a free cysteine group into human Fv fragments followed by thiol coupling with maleimideactivated PEG. He et al. (1999) introduced a cysteine group into trichosanthin (the native form of which has no cysteines) for PEGylation. More exotic approaches have also been used. Sato (2002) used enzymatic catalysis with microbial transglutaminase for site-specific PEGylation of recombinant interleukin-2.
In many cases modification of a target substance by only one polymer molecule may achieve the desired pharmacological or other effects. One example is PEG-Intron which involves monoPEGylation of an interferon by a 12 kDa PEG (Wang et al., 2002) . However in other cases more extensive PEGylation may be required, e. g. total addition of 20 to 60 kDa PEG (Fung et al., 1997; Heathcote et al., 1999; Yamaoka et al., 1994) . Present availability of 20 to 40 kDa functionalised PEGs makes it possible to achieve this with mono-or di-PEGylation. Such low degrees of PEGylation reduces the PEG-protein fractions of varied N, and PEGamers of similar N, which must be separated from each other. Many researchers have related the effects of PEGylation to the large viscosity radius of PEGs (e. g. Clark et al., 1996) . Recent work by the authors suggests that, as measured by (SEC) chromatography, the viscosity radius of a protein that is tetra-PEGylated with 5 kDa PEG is equivalent to that which results from mono-PEGylation with a 20 kDa PEG (Fee and Van Alstine, 2004) . Another reason for reducing N is that negative effects of PEGylation on protein activity decrease with N and such factors are more dominant than the MW of the PEG coupled to the protein. In the case of antibodies and enzymes binding constants tend to directly decrease with N in a semilog manner (e. g. Chapman, 2002; Chapman et al., 1999; Clark et al., 1996; Karr et al., 1986; Veronese et al., 1992) .
The main argument for PEGylation involving more sites is that it allows use of smaller PEGs which may be more rapidly cleared from the body. Non-medical uses of PEG-proteins may also offer situations where multiple PEGylation sites are attractive.
Nevertheless a heterogeneous product mixture results from batch-wise PEGylation that includes, depending on the conditions, un-reacted native protein, un-reacted functionalised PEG, and PEGylated species with a range of PEGylation sites and varying extents of conjugation. Further, functionalised PEG's such as succinimidylpropionic-acid-PEG (PEG-SPA) are readily hydrolysed in water, yielding Nhydroxysuccinimide and un-reactive PEG residues, adding to the product complexity.
Hydrolysis of amino-activated PEG's is generally faster than aminolysis so molar excesses of PEG to protein as high as 50:1 may be used (for example, Brumeanu et al., 1995) . Veronese et al. (1992) described other by-products of PEGylation reaction such as cross-linked PEG-proteins, arising from impurities in commercial PEG reagents, which, although low level contaminants, may be significant in products intended for therapeutic use. Normally monomethoxy PEG reagents (mPEG-x) in which one terminal hydroxyl group on the PEG diol is replaced by a methyl group area used to prevent bifunctional activity such as cross-linking.
Reaction Engineering
Reaction engineering involves controlling the conditions which influence the reaction.
This often involves a trade-off between maximising the extent of the reaction and its specificity versus minimising cost. In biomolecular engineering, conditions must be gentle and the reactor and ancillary equipment must be able to be sterilised. Also, regulatory practices require traceability from end products back to source for all processes and in general it must be shown that all end products have been through identical processes. For these reasons, batch, unidirectional, single-pass processes are universally preferred, and these processes must be simple and robust to minimise variation between batches. In the case of protein PEGylation, the high cost of raw materials (particularly highly purified native protein) implies that maximising reaction extent and specificity are critical objectives.
In general only pure protein preparations are PEGylated. This means that PEGylated proteins, which require additional reaction, separation and analysis are inherently more expensive to produce. The main reasons for not PEGylating crude protein samples (e. g. crude or mildly purified fermentation samples) is to reduce validation (Hoyle, 1991) and separation challenges. These are of particular concern as regards production of PEGylated biopharmaceuticals and may be of less concern for other types of PEGylated-molecules (e.g. pesticides, catalysts, etc.) . This is especially true if the PEGylation reaction can be confined to the target protein in a crude mixture, and such PEGylation helps render the desired PEG-protein sample readily separable from contaminants.
Modern trends are to carry out PEGylations using PEGs functionalised with groups which tend to readily hydrolyse. Such groups, such as NHS or SPA require specific care in regard to storage and often require use of excess molar ratio's of PEGylating agent to protein. This can be costly, especially if such reagents need to be GMP grade. Other reaction complications (and cost concerns) are related to rapid exposure of the PEG reagent to target protein, and controlled termination of the reaction typically via pH modulation. These requirements introduce the need for effective and costly process mixing and monitoring capabilities. Such reagent and process demands tend to reflect the high standards of biopharmaceutical production. If PEG-proteins and related substances are to be produced for less demanding applications it may be possible to work with nonGMP, slower reacting reagents (e. g. PEG-aldehyde, PEGepoxide) which have often been employed in other PEG-related coating applications (Harris, 1992b; Harris and Zalipsky, 1997) .
Protein PEGylation may be carried out in a batch or fed-batch reactor or in a packedbed reactor. A major advantage of the batch or fed-batch reactor is that it is simple to operate and easy to clean between batches. As such this is the main approach of choice. Disadvantages are that the reactants, products and by-products remain in contact throughout the reaction process and must be separated after completion of the reaction. Batch reaction is particularly suitable when site-specific PEGylation chemistry is used. When a less specific chemistry is used, such as conjugation via ε-amino groups of lysine residues, both under-and over-PEGylated products are inevitable. Mainly mono-PEGylated protein will result from a fed-batch operation if the protein is kept in large excess and activated PEG slowly added as the limiting reagent but unless there is a partition or other way to constantly remove the PEGylated protein from the reactor, multiple PEGylation will result once appreciable amounts of PEGylated protein accumulate in the system. In other words, this method can control the extent of PEGylation but only at the cost of very low protein conversion. Targeting a specific PEGylation extent greater than N= 1 will invariably result in under-and over-PEGylated forms.
Packed-bed or "on-column" PEGylation has been used in attempts to influence both the site and the extent of conjugation. Solid-phase synthesis has been used for sitespecific oligopeptide PEGylation (Felix, 1997) . In this approach, the molecule is built up by tethering a peptide sequence to a solid phase and then adding peptides one at a time, with bi-functional PEG being attached at a specific step in the sequence. It may have some promise for smaller MW substances but its use for PEGylation of larger molecules such as most proteins appears questionable.
On-column PEGylation may be achieved by immobilising the protein to the solid phase during PEGylation, achieving at least partial separation by washing the column free of reactants and by-products in the mobile phase, and then eluting the product(s). Monkarsh et al. (1997) used this technique to PEGylate α-interferon before separating the positional isomers. They bound the native protein to an ion exchanger and then passed activated PEG through the column. Because PEGylation generally weakens (IEX) interactions, they were able to elute the PEGylated protein from the column at salt concentrations that did not elute the native form. They then replaced the equivalent amount of protein that was eluted and repeated the process. Unfortunately, this had virtually no effect on the distribution of PEGylated variants achieved in relation to batch PEGylation as the bound protein still presents multiple binding sites to the activated PEG in the mobile phase.
A better approach may be to bind the activated PEG to the solid phase and pass the protein through the column. As long as the density of the PEG on the surface is not so great that a single protein molecule could bridge between two adjacent PEG molecules, mono-PEGylation would occur, with the PEGylated form then remaining bound to the column until it can be eluted after washing. Binding the PEG to the solid phase requires adding a second functional group to the PEG molecule, which might then have to be removed from the final PEG-protein product to avoid potentially negative clinical effects. Also, PEGylated surfaces are well-known to exclude proteins in solution, so encouraging the protein to come into close enough contact with the PEG to allow reaction with the conjugation group might prove difficult.
Others have attempted to use on-column PEGylation to orientate the protein so that the active site of the protein is held towards the solid-phase interface, thus hindering conjugation at sites that might interfere with activity. This may result in a higher activity of the PEGylated form over forms that are PEGylated at random in free solution. Lee and Lee (2004) reported that this technique gave site-specific monoPEGylation of interferon at the N-terminus using reductive alkylation under acidic conditions with a yield of 50 to 60% of loaded native protein. However, the binding was on a cation exchange column, which would result in a largely random orientation of the protein on the exchanger surface and would thus be unlikely to significantly affect reaction specificity. Kinstler et al. (2002) demonstrated site-specific PEGylation of recombinant human granulocyte colony stimulation factor (rhGCSF) at the N-terminus using reductive alkylation under mildly acidic free-solution conditions (pH 5.0). Wylie et al. (2001) showed that pH can significantly affect the PEGylation site, giving a preferential PEGylation of histidine with succinimidyl carbonyl-PEG under acidic free-solution conditions. Therefore, the on-column method of Lee et al., while achieving the advantage of reaction and isolation in a single unit operation, may not affect positional isomerism or PEGylation extent. Baran et al. (2003) used an affinity media (Red Sepharose™ CL-4B, GE Healthcare) to protect the active site from access by the PEGylation reagent during on-column PEGylation of catalase and asparaginase. They reported higher retention of native activity for both proteins compared with literature values related to free solution PEGylation. However some of the latter studies used different chemistry, making it difficult to attribute higher retentions of activity to the solid phase technique rather than to reaction chemistry. As a result the evidence presented for protection of the active site by affinity immobilisation was only indirect.
A different approach to column PEGylation, size exclusion reaction chromatography (SERC), was used by Fee (2003) , who exploited the differing linear velocities of species of differing sizes in SEC to control reaction extent. This method is analogous to membrane reactors, which, for example, may be used to control the extent of protein hydrolysis by removing products via a semi-permeable membrane once their molecular weights fall below a certain level. In SERC, the objective is to remove products whose size is larger than the reactants (as in PEGylation). Single pulses of the protein and the activated PEG are injected into the column sequentially, lowest molecular size first. The larger reactant has a higher linear velocity so catches up to the smaller one such that a moving reaction zone is formed as they migrate through the column. As the PEGylated protein formed is larger than either reactant, it moves ahead of the reaction zone. With a sufficient length of column, both reaction and separation of all species can be achieved in a single unit operation. Control of running buffer flow rate, PEG and protein concentrations and injection volumes, pH, temperature and media type allow full control over the reaction residence time and subsequent separation. Ideally, the activated PEG should be larger than the native protein so that a reaction front forms as the PEG catches up with the protein in the column. This way, the faster moving PEGylated form will move ahead of the reaction front through the (inert) protein band and so escape further PEGylation. In this mode, the native protein is converted from the trailing edge of the band toward the leading edge, leaving low molecular weight by-products behind. The approach is particularly useful with regard to PEGylation as many native proteins of therapeutic interest are less than 20 kDa, and smaller in colloidal size than even a 5 kDa PEG molecule.
Purification Engineering

General Considerations
Normally, in designing a bioseparation strategy, one seeks to exploit differences in physicochemical properties. These properties routinely include molecular size (often indirectly inferred from differences in molecular weight) for size exclusion chromatography and membrane separations, isoelectric point and surface charge distribution for ion exchange chromatography and relative hydrophobicity for hydrophobic interaction chromatography. Affinity chromatography, which targets highly specific sites on the protein, is a favored method as it allows for significant target purification and concentration.
Purification of PEGylated proteins involves removing all molecular species that are not part of the target product. In some cases PEG-protein biopharmaceuticals may be comprised of a mixture of PEG-proteins of different grafting ratio (N). Such a mixture may offer optimal performance in terms of activity versus in vivo half life. Of course mixtures of PEGamers may be suitable as therapeutics only if they can be reproduced in type and relative amounts batch to batch.
If target proteins in a crude protein mixture (e. g. fermentation broth) are PEGylated in a specific manner then PEGylation may aid their preliminary purification. For example the log of the partition coefficient (K) of PEG-modified proteins between the two aqueous phases in a PEG-dextran two polymer, or PEG-salt two-phase system increases directly with degree of PEGylation of the protein (Delgado et al., 1997; Harris and Zalipsky, 1997; Karr et al., 1986) . This is fortuitous as cell debris, endotoxin, some proteins and other contaminants often partition in favour of the non-PEG-rich phase. Other approaches may also be possible such as selective precipitation of PEG-proteins by calcium or other divalent salts. In such cases subsequent purification will be performed in a manner similar to the normal situation where a pure protein sample is PEGylated.
PEGylation of a pure protein sample creates two basic types of purification challenges. The first is involves separation of PEG-proteins from other reaction products including, but not necessarily limited to, unreacted PEGs and proteins. The second is sub-fractionation of PEG-proteins on the basis of their degree of PEGylation and positional isomerism. One would think that effecting such separations should be straight-forward but it can be complicated by several factors related to the nature of PEG polymers.
As noted above, such polymers are neutral, hydrophilic and soluble in various aqueous solutions, as well as being somewhat hydrophobic and soluble in some organic solvents such as acetone, or azeotropes (e.g. methanol/water 3:1 v/v). The amphipathic nature of PEG appears related to the conformations it can have in solution (Karlström, 1985) and tend to make PEGs weak surfactants (detergents). As temperature affects these conformational states PEGs tend to be thermally responsive and their solubility in aqueous solution decreases inversely with temperature. PEGs are normally soluble in aqueous solution up to 100 o C but addition of salts can drastically reduce their solubility. Fuctionalisation also affects PEG solubility. PEGs are normally neutral but they can interact via their ether oxygens and terminal groups in various weak interactions such as hydrogen bonding or ion chelation. They are often used, together with different salts, to promote selective precipitation or crystallisation of proteins. PEGs represent fairly high MW polymers and they tend to increase the viscosities of aqueous solutions. They non-specifically adsorb to surfaces and in so doing affect the physical and other properties of such surfaces including charge group pKa's and protein adsorption (Harris, 1992b; Harris and Zalipsky, 1997 Chapman, 2002; Harris, 1992b; Harris and Zalipsky, 1997; Nho et al., 1992) . In many cases the methods listed in Table 1 Given the above, plus the great variation in proteins which are PEGylated and their degree of PEGylation, it may not be possible to identify a generic separation process for PEG-proteins. However it is possible to list some general considerations. There will be at least three fractions to isolate (PEGs, PEG-proteins and native proteins).
The PEG-protein fraction will need to be subfractionated on the basis of N with perhaps some PEGamer fractionation. Given that PEGs are colloidally active and can affect process operating conditions (foaming, viscosity, fouling) they should be removed as early as possible. One can take advantage of their properties (size, neutrality, hydrophilicity, amphipathic nature) and perhaps use filtration or other (e. g.
HIC, SEC) approaches. Native proteins will tend to not be very "PEG-like" and may be isolated on the basis of their different properties (e.g. often smaller viscosity radii, greater surface charge, exposed affinity groups) using methods such as size exclusion, ion exchange, HIC, affinity chromatography, or even solubility. PEG-proteins will vary in properties between those which may be modified slightly (e. g. low N and small MW PEGs) to those more PEG-like in character. Surface property variation may be related to the weight fraction of PEG in the PEG-protein conjugate (Delgado et al., 1997) while size and other properties are related to volume fraction (keeping in mind the large viscosity radius contribution of the PEG) (Clark et al., 1996; Fee and Van Alstine, 2004) . Thus approaches related to fractionation on the basis of size, charge, and hydrophobicity may be successful in terms of separating PEG-proteins from other reaction product mixture components. IEX media is generally eluted at higher salt concentration while HIC media is loaded under high salt; so normally HIC follows IEX. Thus it would thus appear that size exclusion followed by ion exchange approaches and then HIC may form the basis for a generic approach. As noted above SEC and IEX appear to be commonly used methods. PEGamer fractionation may require more exotic methods such as the above approaches with very long linear gradients, or HIC using complex and varied mobile phases.
There is presently no method of choice for PEGamer resolution on the preparative scale. Monkarsh et al. (1997) were able to separate 11 positional isomers of monoPEGylated α-interferon using cation exchange chromatography but only in analytical scale. Differences between isomers in isoelectric point (pI), surface charge distribution and relative hydrophobicity are likely to be subtle and it is doubtful that these can be exploited at the preparative scale. Fortunately, to date at least, regulatory authorities appear to not have insisted on producing single-PEGylation site, molecularly defined PEGylated therapeutic proteins.
Size-Based Separations
The species to be separated after PEGylation may be classified according to molecular weight, as shown in Table 2 .
Desalting with gel filtration will remove low molecular weight species and allow buffer exchange into a suitable buffer, such as a volatile buffer prior to freeze drying. Maeda et al. (1992) used hollow fibre ultrafiltration to remove < 40,000 MW species from the product mix after PEGylation of bilirubin oxidase. Bailon and Berthold (1998) concentrating PEGylated tumour necrosis factor receptor type I (TNF-RI), noting that unacceptable product losses occurred when using 10 kDa molecular weight cutoff membranes. This is surprising, as TNF-RI has a molecular weight of 55 kDa, and was mono-PEGylated with a 30 kDa PEG. The authors advised that they normally disregard the contribution of the PEG adduct when choosing a suitable pore size for ultrafiltration membranes (Edwards et al., 2003) .
Low molecular weight hydrolysis and PEGylation reaction by products and unconjugated PEG species are generally only weakly retained by ion exchange, so this could be used to remove these species. However, binding of PEGylated proteins becomes weaker as PEGylation extent increases. Therefore higher PEGylated species may well be contained in the flow through fraction. This is discussed in more detail below.
Size exclusion chromatography can be used to separate PEGylated species from other components but the effectiveness will depend greatly upon the molecular sizes of the species involved. While SEC has generally been thought to be unreliable for identifying PEGylated proteins from their elution profiles (Christakopoulos et al., 1998; Fortier and Laliberte, 1993; McGoff et al., 1988; Veronese, 2001 ) SEC columns calibrated in terms of molecular size rather than molecular weight give consistent results for protein and PEG standards (Benoit et al., 1966; Fee and Van Alstine, 2004) . Using this technique, Fee and Van Alstine (2004) found that the size of PEGylated proteins can be accurately predicted from the radius of an hypothetical PEG molecule having the same molecular weight as the total conjugated PEG and the native protein radius, using the following equation: ; where R h,PEGprot is the viscosity radius of the PEGylated protein; R h,prot is the viscosity radius of the native protein; and R h,PEG is the viscosity radius in free solution of a single PEG molecule of the same molecular weight as the total conjugated PEG.
For globular proteins, the viscosity radius (in Ångströms) of the molecule (assuming a spherical shape) is related to its molecular weight in Da, M r, prot , by equation 2 (Hagel, 1998) 
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As a general rule of thumb, preparative-scale size exclusion chromatography separates proteins well only if they differ in molecular weight by about 100%. Thus a protein of molecular weight x can be separated efficiently from one of 2x. This corresponds to a size ratio between molecules, calculated from equation 2, of 1.26. In terms of size, a PEG molecule has a much larger hydrodynamic radius than a protein of corresponding molecular weight. Therefore, conjugating a single PEG of the same or higher molecular weight to protein adds much more to the molecular radius than simply doubling the protein molecular weight so these species should be easily separable by SEC. For low PEGylation extent then, SEC will be effective but the resolution between peaks will be expected to decrease as PEGylation extent increases. Although the sizes of the target PEGylated species are equal, SEC can purify from its under-and over-PEGylated forms a protein that is mono-PEGylated with a 20 kDa PEG but not the same protein tetra-PEGylated with a 5 kDa PEG. It is worth repeating that the guideline for acceptable resolution between species is for obtaining acceptable yield and purity in preparative-scale purifications. For analytical purposes, peak elution volumes and therefore species can often be clearly identified at higher PEGylation extents.
Not shown in Table 2 (Delgado et al., 1997; Karr et al., 1986 ).
Charged-Based Separations
As noted above common problems with purification of PEG-proteins by IEX and other capture methods include a need to work with dilute feed solutions and fouling.
In addition adsorption capacities in terms of mg protein per ml are often 10X lower than is normal for non-PEGylated proteins. However this may to some extent reflect the fact that much of volume of PEG-proteins is related to PEG not protein.
Capacities of media in terms of mass per ml may be more comparable. IEX approaches offer the possibility to effect some separation of PEGs, native proteins, and PEGylated proteins in one step. Given the generally satisfactory performance of SEC media, IEX media is the most commonly used media which may be in need of improvement.
Most purification methods in the literature use ion exchange at some stage in the process. Invariably it is reported that interaction weakens with increased PEGylation extent. To the authors' knowledge, there has been no systematic study of the effects of PEGylation extent, the molecular weight of the PEG adducts or the binding site on ion exchange behaviour.
PEG is a neutral polymer but it may affect the charge properties of proteins in three ways. First, the presence of the PEG conjugate may shield the surface charges of a protein, thereby weakening the binding to ion exchange resins. Second, conjugation to amino acid residues that alter their charge nature (e. g. convert amine groups to amides) or take on charge at certain pH values alter this potential charge and will affect the isoelectric point (pI). Third, protein surface localised PEGs may hydrogen bond with acidic or other groups and raise their pKa (Delgado et al., 1997) . Azarkan et al. (1996) used thiol PEGylation as a strategy to purify chymopapain for x-ray crystallography and found that PEGylated species bound more weakly to a cation exchanger. Since the pI of the protein was unaltered by PEGylation, they concluded that charge-shielding was responsible. Hecht et al. (1996) separated PEGylated from native brain-derived neurotrophic factor (BDNF) using a preparative electrofocussing device but were unable to separate BDNF of differing PEGylation extent. The authors suggested the reason for this was that the species with differing degrees of PEGylation "probably" varied only in the length of PEG chains attached rather than the number, and therefore the pI's of the PEGylated species would not differ. However, the origin of the PEGylated material was from authors (Chamow et al., 1994) PEGylation dramatically affects molecular size and this may be reflected in lowered ion exchange media capacity due to associated decreases in diffusivity or through steric. PEGylated surfaces repel proteins (Harris, 1992b; Harris and Zalipsky, 1997) ,
and bound PEG-proteins may hinder adsorption of other PEG-proteins. Brumeanu et al. (1995) found that highly PEGylated species were contained in the flow through fraction during anion exchange, while mildly PEGylated species eluted at lower salt concentrations than native proteins. They also noted that prior removal of free PEG was extremely important in obtaining good resolution. This was also reported by McGoff et al. (1988) in charge-reversal capillary zone electrophoresis. Sherman et al. (1997) and Olson et al. (1997) showed that increased PEGylation decreased the conductivity required for elution. However, under the conditions studied which featured a fairly steep elution gradient the di-PEGylated form was not sharply separated from the mono-PEGylated form. In addition a tail on the flow through peak extended to the mono-PEGylated peak.
Similar results were observed with SP Sepharose™ Fast Flow media and other commercial cation exchange media (data not shown), though with lower capacities, broader peaks and poorer resolution. In a variety of situations the prototype media appears to not only offer good selectivity but also much reduced fouling and the ability to work with 2x more concentrated feed solutions at linear flows of > 100 cm/hr. Note that faster flow rates may not be desired due to the large viscosity radii and slow diffusing nature of the PEGylated proteins.
Piquet et al. (2002) 
Hydrophobicity Based Separation
Very little work has been done on utilising hydrophobicity for separation. Clark et al. (1996) fractionated growth hormone modified with 5 kDa PEG-NHS (N = 0 to 6) using a process which began with HIC fractionation of the reaction product mixture on a phenyl TSK 5PW™ HIC column loaded at 2.75 mg of protein per ml media followed by elution with salt gradient 0.35M NaCitrate, 0.05M Tris pH 7.5 to 0.05M
Tris at 60 cm/hr for 7 column volumes. This was followed by ultrafiltration, buffer exchange on a G-25 Sephadex™ column and then cation exchange on SP Sepharose
High Performance media loaded at 2.1 mg protein per ml media and eluted with 7 column volumes and a gradient from 0 to 300 mM NaCl in 25 mM NaAcetate of N amers on SP Sepharose High Performance media run at pH 4 and loaded at 2.1 mg protein per ml gel with elution in 7 column volume gradient from 0 to 300 mM NaCl in 25 mM.
PEG forms a biphasic system at high salt concentrations. Vincintelli et al. (1999) examined the salting out effects of potassium fluoride and ammonium sulphate on PEG and related these to the effectiveness of hydrophobic interaction chromatography. They showed that PEG 4600 and native bovine β-lactoglobulin coeluted on Fractogel TSK-Butyl 650 but that the conjugate was more tightly bound to the matrix, concluding that conformational changes to the protein may contribute to the surface hydrophobicity. Another explanation is that the PEG may surround the surface of the protein in such a way as to shield hydrophilic regions while leaving hydrophobic regions exposed. The authors and colleagues have noted interesting results with HIC (not shown) and this is an approach that requires more investigation.
Immunoaffinity and Other Specific Affinity Interactions
PEGylation can affect affinity interactions in two basic ways depending on whether the target or the binding protein is PEGylated. A general observation is that binding constant logarithms increase directly with N. This holds for enzymes, antibodies and other affinity proteins. However PEGylation may also eliminate binding depending on the site of modification. Karr et al. noted that significantly PEGylated polyclonal antibody preparations were capable of recognising and binding antigen and could be used for immunoaffinity separations (Karr et al., 1986) . They also noted that PEGmodified protein A was also capable of binding antibody (Karr et al., 1988) . Many studies (Chapman, 2002) suggest that even low level PEGylation of antibodies can significantly affect Fc receptor binding. Veronese et al. (1992) elucidating these properties and effects should pay large dividends in terms of helping engineers design processes to deliver effective new products at reasonable costs.
Research areas of particular interest also include improving control over PEGylation site, and separation of both PEG-reaction product mixtures as well as PEGamers.
Some applications may benefit from the use of non-classical approaches such as twophase partitioning, or on the column methods such as size exclusion reaction chromatography. While classic separation methods such as SEC, IEX and HIC are useful there is some concern that present media, which has typically been designed for macromolecules of smaller viscosity radius than many PEG-proteins, do not offer optimal performance. Though much work needs to be done it is promising to note that in many cases PEGylation may render proteins more similar and amenable to related process engineering solutions. (Wylie et al., 2001) anti-tumour necrosis factor-α scFv fragment 5, 20, 40 kDa maleimide size exclusion analytical separation (Yang et al., 2003) 
Prototype CIEX Resin
Column: 0.92 mL HR 5/5 Load: 1.0 mL Flow rate: 100 cm/hr Total Bound (including PEG) Exceeds 9.6 mg/mL resin Sample: Reaction Product from combining 5.01 mg/mL cytochrome C 7.88 mg/mL mPEG 2 -NHS 20 kDa Applied Sample Contains: 2.35 ± 0.12 mg/mL native cytochrome C 6.48 ± 0.32 mg/mL mono-PEG cyt C 2.13 ± 0.11 mg/mL di-PEG cyt C 2.28 ± 0.11 mg/mL free mPEG 20 kDa Unknown quantity of low molecular weight UV active reaction and PEG reagent hydrolysis by-product(s)
